Cyramza ramucirumab: Additional Phase III data

Additional data from the double-blind, international Phase III RAINBOW trial in 665 patients with advanced gastric cancer refractory to or progressive after first-line chemotherapy containing platinum and fluoropyrimidine with or without an anthracycline showed that 8 mg/kg IV Cyramza every 2 weeks plus paclitaxel led to a median OS, the primary endpoint, of 9.6 months vs. 7.4 months for placebo plus paclitaxel (p=0.0169). Cyramza plus paclitaxel led to a median PFS, a secondary endpoint, of 4.4 months vs. 2.9 months for placebo plus paclitaxel (p<0.0001.) Additionally, Cyramza plus paclitaxel met the secondary endpoint of improving ORR vs. placebo plus paclitaxel (28% vs. 16%, p=0.0001). Data were published in The Lancet Oncology. Eli Lilly previously reported that Cyramza plus paclitaxel met the primary endpoint and secondary PFS endpoint (see BioCentury, Sept. 30, 2013). ...